WallStSmart

Enovis Corp (ENOV)vsGE HealthCare Technologies Inc. (GEHC)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

GE HealthCare Technologies Inc. generates 821% more annual revenue ($20.98B vs $2.28B). GEHC leads profitability with a 9.1% profit margin vs -49.9%. GEHC appears more attractively valued with a PEG of 1.84. GEHC earns a higher WallStSmart Score of 57/100 (C).

ENOV

Buy

57

out of 100

Grade: C

Growth: 8.0Profit: 3.0Value: 6.3Quality: 5.5
Piotroski: 4/9Altman Z: -0.34

GEHC

Buy

57

out of 100

Grade: C

Growth: 4.0Profit: 6.0Value: 5.7Quality: 4.5
Piotroski: 2/9Altman Z: 1.34
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ENOVUndervalued (+34.9%)

Margin of Safety

+34.9%

Fair Value

$35.03

Current Price

$23.78

$11.25 discount

UndervaluedFair: $35.03Overvalued

Intrinsic value data unavailable for GEHC.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ENOV2 strengths · Avg: 10.0/10
Price/BookValuation
0.9x10/10

Reasonable price relative to book value

EPS GrowthGrowth
153.1%10/10

Earnings expanding 153.1% YoY

GEHC2 strengths · Avg: 8.0/10
P/E RatioValuation
15.6x8/10

Attractively priced relative to earnings

Price/BookValuation
2.8x8/10

Reasonable price relative to book value

Areas to Watch

ENOV4 concerns · Avg: 3.0/10
PEG RatioValuation
1.904/10

Expensive relative to growth rate

Market CapQuality
$1.25B3/10

Smaller company, higher risk/reward

Operating MarginProfitability
3.6%3/10

Operating margin of 3.6%

Return on EquityProfitability
-77.0%2/10

ROE of -77.0% — below average capital efficiency

GEHC4 concerns · Avg: 2.8/10
PEG RatioValuation
1.844/10

Expensive relative to growth rate

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

EPS GrowthGrowth
-30.9%2/10

Earnings declined 30.9%

Altman Z-ScoreHealth
1.342/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : ENOV

The strongest argument for ENOV centers on Price/Book, EPS Growth.

Bull Case : GEHC

The strongest argument for GEHC centers on P/E Ratio, Price/Book.

Bear Case : ENOV

The primary concerns for ENOV are PEG Ratio, Market Cap, Operating Margin.

Bear Case : GEHC

The primary concerns for GEHC are PEG Ratio, Piotroski F-Score, EPS Growth.

Key Dynamics to Monitor

ENOV profiles as a turnaround stock while GEHC is a value play — different risk/reward profiles.

ENOV carries more volatility with a beta of 1.49 — expect wider price swings.

GEHC is growing revenue faster at 7.4% — sustainability is the question.

GEHC generates stronger free cash flow (112M), providing more financial flexibility.

Bottom Line

ENOV scores higher overall (57/100 vs 57/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Enovis Corp

HEALTHCARE · MEDICAL DEVICES · USA

Enovis Corporation is a global medical technology company. The company is headquartered in Wilmington, Delaware.

GE HealthCare Technologies Inc.

HEALTHCARE · MEDICAL DEVICES · USA

GE HealthCare Technologies Inc. provides medical technology, pharmaceutical diagnostics, and digital solutions in the United States. The company is headquartered in Chicago, Illinois.

Want to dig deeper into these stocks?